You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

 

Online download statistics by month:

Online download statistics by month: November 2021 to November 2024

AbstractFullPdf
Nov 2021423018
Dec 2021128014
Jan 202213606
Feb 202278011
Mar 2022232015
Apr 202213009
May 2022132017
Jun 2022160014
Jul 202211407
Aug 2022158017
Sep 2022166021
Oct 2022186014
Nov 202211807
Dec 202210207
Jan 20239806
Feb 2023128016
Mar 202313808
Apr 202398012
May 202382011
Jun 20233802
Jul 202368017
Aug 202382014
Sep 20235807
Oct 202392020
Nov 20237006
Dec 20237005
Jan 20244003
Feb 20243806
Mar 20247607
Apr 20246208
May 202438011
Jun 20246302
Jul 202480010
Aug 20248506
Sep 2024104013
Oct 202474018
Nov 20244404
Total39890389